The Latest Breaking News from LLY

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Barchart · Oct 23, 2024

Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes, obesity, and eczema markets, is it a must-have in your healthcare portfolio? Read on to…

StockNews.com · Oct 23, 2024

Eli Lilly Earnings Preview: What to Expect

Eli Lilly will release its third-quarter earnings this month, and analysts anticipate a considerable bottom-line growth.

Barchart · Oct 21, 2024

3 Top Healthcare ETFs to Buy for Diversified Exposure

Healthcare ETFs offer diversified exposure across resilient subsectors and combine defensive qualities with long-term growth potential. Therefore, investors could consider buying strong healthcare ETFs, such as iShares U.S. Healthcare (IYH), Vanguard Health Care Index Fund (VHT), and The Health Care Select Sector (XLV). Read more….

StockNews.com · Sep 2, 2024

3 Mega-Cap Stocks Not Named Nvidia Up More than 40% in 2024

Shares of mega-cap stocks such as Walmart, Meta Platforms, and Eli Lilly have surged over 40% in 2024, outpacing the broader markets by a wide margin.

Barchart · Aug 29, 2024

Eli Lilly Launches Discount Anti-Obesity Drug

The company claims the Zepbound doses cost 50% less than competing drugs

International Business Times · Aug 27, 2024

Up 58% YTD, is Eli Lilly Stock Still a Buy?

The pharmaceutical giant has already delivered massive gains this year, but Wall Street analysts have only gotten more bullish on the maker of Mounjaro and Zepbound.

Barchart · Aug 19, 2024

3 Gene-Editing Stocks to Buy for Future Health Advances

With ever-expanding operations and rapid technological innovations, the gene-editing industry looks poised for solid long-term growth. Thus, investors could consider solid stocks Eli Lilly (LLY), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). Continue reading.

StockNews.com · Aug 14, 2024

Eli Lilly Stock: Analyst Estimates & Ratings

Eli Lilly has significantly outperformed the broader market over the past year, and Wall Street analysts are bullish about the stock’s prospects.

Barchart · Aug 9, 2024

Stock Market Today: Stocks Rally as Recession Fears Ease

Initial jobless claims fell more than expected last week, which helped calm fears of a slowing labor market.

Kiplinger · Aug 8, 2024